Loading chart data...
Merck is surging today following the announcement of positive topline results from the Phase 3 INTerpath-001 trial of its personalized cancer vaccine in combination with Keytruda. The study successfully met its primary endpoints of recurrence-free survival and distant metastasis-free survival in patients with completely resected Stage IIB-IV melanoma. This landmark clinical success is driving significant investor optimism, with partner Moderna also seeing substantial gains in sympathy as the market reacts to the validation of this mRNA-based therapeutic approach.
That explains the day. Whether MRK is a business worth owning is a longer question. Koyfin has the ten-year financials, margin history and valuation to answer it — 20% off for WhyTheMove readers.
No significant catalyst events detected.
MRK moved for a reason you can read above. What the company earns, owns and guides to is a separate record. Koyfin is where the question moves from today's move to the business behind it — analyst estimates, filings and earnings transcripts.
Research MRK in Koyfin →7-day full-access trial · 20% off paid plans